However, TNF signaling pathways still represent a potential therapeutic target for residual cardiovascular risk; indeed, additional molecular targets belonging to the TNF superfamily, such as Tumor Necrosis Factor-Alpha-Related Apoptosis-Inducing Ligand (TRAIL), Tumor Necrosis Factor-like Weak inducer of apoptosis (TWEAK), and CD40L, are currently under investigation for the treatment of rheumatologic diseases and cancer and the results of ongoing trials are awaited [169]. This evidence concerns the gene TNF and cancer.